'We can't rely on foreign sources': Trump administration awards US generics producer $354M contract

The Trump administration announced a $354 million drug contract with a generic medicine manufacturing company providing “immediate U.S.-based capacity” to produce pharmaceutical ingredients and expand advanced manufacturing capacity, reducing reliance on overseas supply chains.

Phlow Corporation will lead the effort, the U.S. Department of Health and Human Services said in a statement. The Virginia-based company is also planning a new manufacturing facility in-state.